There is ongoing debate regarding the optimal management of anemia in post-transplant patients, particularly surrounding the use of erythropoietin (EPO) and newer hypoxia-inducible factor prolyl-hydroxylase inhibitors (HIF-PHIs). This evidence concerns the gene EPO and anemia (phenotype).